Coulter Partners secures Dieter Weinand as Board Chair for AstriVax Therapeutics

AstriVax Therapeutics is a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary plug and play plasmid-based Launch-iT technology.

US-based Dieter Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry.

“AstriVax Therapeutics’ Launch-iT technology platform and its immunotherapy drug candidates for the treatment of chronic infectious diseases are extremely impressive and I am very excited to be joining at this significant moment in the company’s journey,” said Dieter Weinand, Chair of the Board of Directors of AstriVax Therapeutics. “I am looking forward to working with Hanne and the team as we progress the company’s pipeline through clinical development, further expand our network globally with companies and investors, and make genuine positive impacts on patient outcomes.”

“On behalf of the entire AstriVax Therapeutics team and our Board, I would like to welcome Dieter Weinand as our new Chair,” said Hanne Callewaert, Ph.D., co-founder and CEO of AstriVax Therapeutics. “Dieter brings with him a phenomenal amount of experience as a global pharmaceutical leader. He shares our entrepreneurial drive and our mission to improve the lives of patients affected by chronic diseases. I am honored to have Dieter on board and look forward to working alongside him in expanding our network globally among investors and potential future partners.”

Dr. Callewaert added, “I would also like to thank Coulter Partners for their outstanding, collaborative and truly trans-Atlantic effort. Their expert and competent team quickly identified Dieter, a well-known industry veteran within their extensive network, making the search for a US-based Chair for our Belgian company a remarkably positive experience.”

----

Dieter Weinand, Chair of AstriVax Therapeutics Board of Directors

During his career, Dieter Weinand has held a number of senior roles leading business operations around the world for companies including Bayer, Pfizer, Bristol Myers Squibb and Sanofi. He has led the development, launch and marketing of products in therapeutic areas such as cardiovascular disease, oncology, immunology, respiratory and inflammatory diseases. Mr. Weinand is currently a member of the Board of Coya Therapeutics and Replimune, Chairman of the Board of Confo Therapeutics, and Executive Chairman of the Board of Mnemo Therapeutics. He earned an M.S. in Pharmacology and Toxicology from Long Island University, New York, and a B.A. in Biology from Concordia College, New York.

About AstriVax Therapeutics

About Coulter Partners